BioSpace News Archive

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, reported financial results for the second quarter ended June 30, 2023.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2023 financial results and corporate updates.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the second quarter ended June 30, 2023.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.

Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, announced financial results for the second quarter ended June 30, 2023.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases, today reported its financial results for the second quarter ended June 30, 2023.

Gossamer Bio, Inc. (Nasdaq: GOSS) today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the second quarter ended June 30, 2023, and provided a business update.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023.